Director David H. Deming of Phio Pharmaceuticals Corp. filed a Form 4 on November 16, 2026, disclosing open-market purchases of 12,000 shares of common stock across two transactions on November 12 and November 13, 2026.
Key Highlights
- First purchase: 9,000 shares of common stock acquired on November 12, 2026 at $0.8136 per share.
- Second purchase: 3,000 shares of common stock acquired on November 13, 2026 at $0.8334 per share.
- Total beneficial ownership: 61,800 shares following the two reported transactions, held directly.
- Footnote disclosure: The beneficial ownership figure includes shares of common stock underlying unvested restricted stock units, according to the filing.
- Transaction codes: Both transactions were coded "P" (open-market purchase) with no 10b5-1 plan box checked.
- Signing authority: The form was signed by Lisa C. Carson as attorney-in-fact on November 16, 2026.
Deming's Two-Session Purchase of Phio Pharmaceuticals Common Stock
According to the Form 4 filed with the U.S. Securities and Exchange Commission, David H. Deming, a director of Phio Pharmaceuticals Corp. (NASDAQ:PHIO), purchased a combined 12,000 shares of the company's common stock (par value $0.0001) over consecutive trading sessions. The first transaction, dated November 12, 2026, involved 9,000 shares at a price of $0.8136 each. The second, dated November 13, 2026, covered 3,000 shares at $0.8334 each. Both transactions are reported as direct ownership and carry a "P" transaction code, indicating open-market purchases.
Phio Pharmaceuticals Corp. is a biopharmaceutical company. The filing notes that Mr. Deming's total beneficial ownership of 61,800 shares following these transactions includes shares of common stock underlying unvested restricted stock units, as stated in the footnote to the filing. Prior to the November 12 purchase, the implied starting position would have been 49,800 shares, based on the sequential reporting in the filing. No derivative securities transactions were reported in Table II of the form.
The filing was submitted on November 16, 2026, and was signed by Lisa C. Carson acting as attorney-in-fact for the reporting person. No amendment date was indicated, suggesting this is an original filing rather than a revision to a previously submitted Form 4.
What Was Disclosed
Director David H. Deming disclosed two open-market purchases of Phio Pharmaceuticals common stock totaling 12,000 shares on November 12 and 13, 2026, bringing his directly held beneficial ownership to 61,800 shares, a figure that includes unvested restricted stock units per the filing.



Please wait processing your request...